Policy Decoded know much more about the OCM than us
Quite frankly I’m bored to tears with the NY OCM and their endless management and staffing dramas.
Office politics, I presume, is like the cape of good hope on a bad day yet month in month out the only official information that ends up in my inbox is some self serving rubbish about how amazing they are.
The xmas missive hasn’t yet landed but I’m sure it’ll have something about Santa and the elves being impressed with their roll out.
Actually if I think about it maybe they should hire in mrs Claus she’ll show them how to to deal with logistics!
New York’s Cannabis Regulator Needs A Coherent Map |
||
 What Happened: New York’s Office of Cannabis Management is in another leadership transition as acting executive director Felicia Reid departs, Chief Administrative Officer Susan Filburn steps in on an interim basis, and Deputy Counsel James Rogers also exits. A recent New York Times investigation into OCM’s handling of Omnium, from licensing through a contested recall, has amplified questions about how the agency sequences enforcement against well-capitalized operators while unlicensed shops continue to operate in full view. At the same time, regulators are highlighting new state data that tie participation in the medical cannabis program to lower opioid use, and they are using that signal to defend the medical framework as a public health asset. Growers and retailers are preparing to launch Metrc, working through trainings, data migration, and integrations on a tight calendar in a market that is already complicated. All of this is playing out in a state with more demand, more population, and more long-term upside than almost anywhere else in the country. |
||
 Why It Matters: New York is building one of the most valuable cannabis markets in the world and doing it while everyone is watching for the stitch that comes loose. Every leadership change slows the small, boring work that makes a system feel predictable, like clear licensing calendars, standard responses to common problems, and enforcement priorities that stay the same from one news cycle to the next. The opioid findings give the state a rare piece of clean evidence that cannabis can sit inside mainstream health strategy instead of living in a separate lane reserved for people who already believe. A well handled seed-to-sale rollout can turn Metrc into something more useful than a compliance chore, because movement data can show where product actually goes and help distinguish sloppy operators from true bad actors. If those pieces come together, lawmakers and city officials will have a much easier time defending the project and investing political capital in it. If they drift or collide, the story hardens around the idea that New York wrote a big cannabis law and then never quite figured out how to run the thing. |
||
|
THC Group Take: You can feel what this system needs when you talk to people from Buffalo, Syracuse, the Hudson Valley, and Queens in the same week. They want someone to say, out loud, what New York’s cannabis market should look like three years from now and then start building backwards from that picture. A serious map would spell out how many unlicensed storefronts the city intends to close or migrate into the legal market, which agencies own each part of that job, and how Metrc data, local inspectors, and community boards fit together instead of bumping into one another. It would stabilize the licensing pipeline so cultivators and retailers can plan capital and hiring on a real calendar, not on rumor and court dockets. It would also give the medical program a defined role in pain management and chronic care, so doctors and health systems know where cannabis fits and patients are not guessing. New York has the money, the people, and the political talent for that kind of work; what it has been missing is a leadership team that wakes up every morning thinking about the whole chess board rather than the latest fire.
